Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of combined Mediterranean diet and physical activity intervention on the gut microbiome and disease progression in individuals with Parkinson's disease: study protocol for a multicenter, randomized controlled pilot study (PRIME study).

Frontiers in aging neuroscience·2026
Same author

α-Synuclein oligomers slow down action potential firing and enhance dopamine release by increasing Cav2.2 currents in midbrain dopaminergic neurons.

The Journal of physiology·2026
Same author

Are glutathionylated aldehyde reductases the missing piece of the "catecholaldehyde hypothesis" in Parkinson's disease? A medical hypothesis concerning the detoxification of 4-hydroxynonenal (HNE) and 3,4-dihydroxyphenylacetaldehyde (DOPAL).

Redox biology·2026
Same author

Selective expression of neurodegenerative diseases-related mutant p150<sup>Glued</sup> in midbrain dopaminergic neurons causes progressive degeneration of nigrostriatal pathway.

Ageing and neurodegenerative diseases·2026
Same author

Systemic Responses Towards Oxy-Inflammation, Hormones, and Mood in Breast Cancer Survivors: Preliminary Evidences from Dragon Boat Endurance Race.

Journal of clinical medicine·2025
Same author

Molecular and cellular determinants of L-Dopa-induced dyskinesia in Parkinson's Disease.

NPJ Parkinson's disease·2024

Related Experiment Video

Updated: Jun 14, 2026

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human &#945;-Synuclein
14:45

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein

Published on: July 29, 2022

Synaptic dysfunction in Parkinson's disease.

Vincenza Bagetta1, Veronica Ghiglieri, Carmelo Sgobio

  • 1Laboratorio di Neurofisiologia, Fondazione Santa Lucia, I.R.C.C.S., 00143 Rome, Italy.

Biochemical Society Transactions
|March 20, 2010
PubMed
Summary
This summary is machine-generated.

Synaptic plasticity in the brain

More Related Videos

Studying Pre-formed Fibril Induced &#945;-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

Related Experiment Videos

Last Updated: Jun 14, 2026

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human &#945;-Synuclein
14:45

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein

Published on: July 29, 2022

Studying Pre-formed Fibril Induced &#945;-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

Area of Science:

  • Neuroscience
  • Synaptic Plasticity
  • Neurodegenerative Diseases

Background:

  • Synaptic plasticity, including long-term depression (LTD) and long-term potentiation (LTP), underpins memory and motor control in the striatum.
  • Parkinson's disease (PD) involves the degeneration of dopaminergic neurons, impacting striatal plasticity and motor symptoms.
  • Dopamine (DA) significantly modulates striatal LTD and LTP, with impairments linked to PD pathogenesis.

Purpose of the Study:

  • To investigate the role of synaptic plasticity alterations in Parkinson's disease (PD) and L-dopa-induced dyskinesia (LID).
  • To explore the impact of chronic L-dopa therapy on striatal synaptic plasticity and the development of abnormal involuntary movements (AIMs).
  • To identify potential therapeutic targets within the NMDA receptor (NMDAR) pathway for PD and LID.

Main Methods:

  • Electrophysiological, molecular, and behavioral analyses in experimental animal models of PD.
  • Investigation of cellular and synaptic changes in the striatum following DA loss.
  • Examination of postsynaptic modifications, particularly NMDAR trafficking and subunit composition, in animals with AIMs.

Main Results:

  • Loss of DA in PD alters striatal synaptic plasticity.
  • Chronic L-dopa therapy can restore plasticity but may lead to L-dopa-induced dyskinesia (LID) with altered synaptic plasticity.
  • Dysfunctional NMDARs in striatal efferent neurons contribute to LID pathogenesis.

Conclusions:

  • Targeting signaling proteins coupled to NMDARs in striatal spiny neurons offers a promising therapeutic strategy.
  • Understanding NMDAR dysfunction is crucial for developing new treatments for PD and LID.
  • Modulating striatal synaptic plasticity holds potential for managing motor symptoms in Parkinson's disease.